Hep C Survey

Quote

Anonymous

Guest
Shocking that the results of the survey were so poor! Come on, what did you think was going to happen when you sold us reps out to Merck! Do you think we are going to lose our credibility with physicians and talk about Victrelis. The drug is a dog and none of us reps are going to do it regardless of how much pressure you get from Merck! Tom K and Theresa M are both morons and sellouts.....none of us reps have any respect for you!
 






Anonymous said:
Shocking that the results of the survey were so poor! Come on, what did you think was going to happen when you sold us reps out to Merck! Do you think we are going to lose our credibility with physicians and talk about Victrelis. The drug is a dog and none of us reps are going to do it regardless of how much pressure you get from Merck! Tom K and Theresa M are both morons and sellouts.....none of us reps have any respect for you!
Click to expand...

speak for yourself.
 












I've worked in pharma like most of us for several years and it amazes me how these survey people think that these things are going to turn out favorably.
1. You never do a survey over a holiday period. People are taking time off and forget everything they have heard.
2. The doctors that take the surveys are typically not the ones we call on.
3. The questions don't make sense. You ask a hundred questions and people start putting down anything.

The fact that you put stock in the surveys says a lot about what you understand about people. (think about the last time you did a survey. I gave up about half way through)

I'm resigned to the fact that the incentive dollars assinged to good survey results were never ours to begin with....
 






Let's face it, "educating" on victrelis is like forcing a square peg in a round hole, it just doesn't seem attractive to the prescribers. The more we talk about victrelis, the more we look like we're trying to sell it, not educate on it. I will not cross that line to try to sell it. The surveys are going to be used to "keep us on our toes" and nervous about our jobs, real motivating isn't it?
 






Anonymous said:
Let's face it, "educating" on victrelis is like forcing a square peg in a round hole, it just doesn't seem attractive to the prescribers. The more we talk about victrelis, the more we look like we're trying to sell it, not educate on it. I will not cross that line to try to sell it. The surveys are going to be used to "keep us on our toes" and nervous about our jobs, real motivating isn't it?
Click to expand...

I have 98% market share, and could care less about surveys, and have no fear of job loss. If one is not ppeneforming, perhaps they should fear the survey.
 






I heard we are planning for layoffs at end of the year because management is getting ready for gilead and all Orals. That is why leadership cut the deal for $ so they could make as much as they could before cuts. I will start looking next quarter.
 






Anonymous said:
I heard we are planning for layoffs at end of the year because management is getting ready for gilead and all Orals. That is why leadership cut the deal for $ so they could make as much as they could before cuts. I will start looking next quarter.
Click to expand...

Here we go again, more gossip, more uninformed rumors. So we will slash our sales force today in preparation for all oral that might come 2-3 years from now. Yeah, ok, that makes tons of sense!
 
























It is not that the new drugs to come are oral. It is that the eliminate the virus with ribovirin alone and your drug is not needed. The Gilead drug does this in just 4 short weeks too.
 


















Anonymous said:
It is not that the new drugs to come are oral. It is that the eliminate the virus with ribovirin alone and your drug is not needed. The Gilead drug does this in just 4 short weeks too.
Click to expand...

Again, please show me the phase three study in Genotype one. You cant, so with that, we have at least 2-3 years before Pegasys becomes irrelevant. There simply is no short term threat to Pegasys, NONE! Some Phase 1/2 study in Genotype 2/3 with 7 patients means absolutely nothing right now. Do you know how many "cant miss" drugs fail in late Phase 3? Come on give me a break. Right Now Pegasys is the undisputed King; every company studies their drug in combination with Pegasys, and there is a simple reason for that.

Just relax, and enjoy the ride for the nest 3-4 years AT LEAST!
 






























Anonymous said:
Again, please show me the phase three study in Genotype one. You cant, so with that, we have at least 2-3 years before Pegasys becomes irrelevant. There simply is no short term threat to Pegasys, NONE! Some Phase 1/2 study in Genotype 2/3 with 7 patients means absolutely nothing right now. Do you know how many "cant miss" drugs fail in late Phase 3? Come on give me a break. Right Now Pegasys is the undisputed King; every company studies their drug in combination with Pegasys, and there is a simple reason for that.

Just relax, and enjoy the ride for the nest 3-4 years AT LEAST!
Click to expand...

Don't make me do this to you...

This is just the beginning of really impressive news for Genotype 1 with 7977. This drug will be fast tracked and will be out much sooner than you think. This data has already added $10Billion in market cap to Gilead in the past month despite Gilead paying $11Billion for VRUS and BMS is about to enjoy the same kind of appreciation due to INHX.

You are delirious if you think its another 3-4 year ride. 12 Week SVR will be coming out soon and I will be happy to show you that data as well. Then there will be the INHX data (or BMS after the acquisition is complete). The whole point is that you are on a dead end train. These new "nucs" are going to be the staple of our area of focus and RBV and Interferon will be gone before you know it. This is a rapidly changing field and you seem to be stuck in a world that is about to go POOF.

If DNA can get ahold of Idenix's Nuc (because it is the only one out there - as slow as the poor thing is) then it might be able to hold onto a very valuable third place. HCV is changing quickly. Question is, will Roche, Merck, Sanofi, J&J jump into the all oral race as well?

So here is the Genotype 1 data. And there will be more to come soon that I will be happy to post for you. Keep asking for it and I will keep posting it.

POOF:

Gilead acquired rights to GS-7977 (formerly PSI-7977) through the $11 billion acquisition of Pharmasset. The deal pushed Gilead to the front of the pack of companies seeking to develop an all-oral regimen for hepatitis C that does away with the need for weekly injections. Bristol-Myers Squibb(BMY_) is paying $2.5 billion to acquire Inhibitex(INHX_) for the same reason.

Further data supporting GS-7977's ability to definitively cure these genotype 1 hepatitis C patients will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI) being held March 5-8 in Seattle.

Gilead's new GS-7977 data announced Thursday night come from a phase II study known as Electron first started by Pharmasset. In this particular arm of the study, 35 patients with genotype 1 hepatitis C (25 treatment-naïve patients and 10 who failed to respond to previous therapy) were treated with GS-7977 plus ribavirin.

After four weeks of this two-drug oral therapy, 100% of patients achieved what is known as a "rapid viral response" or RVR, meaning that the virus could no longer be detected in their blood. RVR is an early and promising signal that drugs are working but it is not definitive proof of a hepatitis C cure. Patients are only deemed cured of hepatitis C -- a sustained virologic response or SVR -- if they have no evidence of the virus in their system 12 weeks after stopping treatment.

At the upcoming CROI meeting Gilead will present further results on some of these 35 patients, specifically showing how many have undetectable virus four weeks after treatment with GS-7977 plus ribavirin ended.
 






Top Bottom
Back
Quote